ArticleAdvanced healthcare materials2024
Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis.
Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Vascularized bone organoids: current advances and a biomimetic platform for osteonecrosis of the femoral head.Bone research · 2026Review
- Engineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation.Bioengineering & translational medicine · 2026Review
- Microengineered bone models: advances and applications of bone-on-a-chip technology.Journal of biological engineering · 2026Review
- Evaluating Complexity in Orthopedic Tissue-on-a-Chip Systems.Advanced healthcare materials · 2026Review
- Tailoring human joint-on-a-chip: from biological principles, materials, to disease modeling.Materials today. Bio · 2026Review
- Next-Generation Joint-on-a-Chip: Toward Precision Mechanical Control in Multi-Tissue Systems.Nano-micro letters · 2026Review
- Modular de- and re-construction of vascularized osteochondral tissues in an Organ-on-Chip dual-compartment platform.Journal of orthopaedic translation · 2026Article
- Harnessing Advances in Bone Tissue Engineering for Design of Bone-on-Chip Systems.Advanced healthcare materials · 2026Review
- Engineering osteoporosis-related bone organoids: a mechanism-module-functional readout framework for disease modelling and biomarker translation.Frontiers in cell and developmental biology · 2026Review
- Evaluation of MSC-Secretome Effects in an Ex Vivo Compartmentalized Osteochondral Interface Model.Stem cells international · 2026Article
- Organoids and organs-on-chips for accelerating R&D and clinical translation in Orthopaedics: Emerging opportunities and regulatory pathways.Journal of orthopaedic translation · 2026Review
- Periosteum Organoid: Biomimetic Design Inspired From the Bone Healing Process.Exploration (Beijing, China) · 2025Review
- A Compartmentalized Joint-on-chip (JoC) Model to Unravel the Contribution of Cartilage and Synovium to Osteoarthritis Pathogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intelligent microstructure materials for diagnosis and treatment of osteoarthritis: progress and AI-enpowered future.Bone research · 2025Review
- An Organ-on-Chip Platform for Strain-Controlled, Tissue-Specific Compression of Cartilage and Mineralized Osteochondral Interface to Study Mechanical Overloading in Osteoarthritis.Advanced healthcare materials · 2025Article
- Sex-stratified osteochondral organ-on-chip model reveals sex-specific responses to inflammatory stimulation.Materials today. Bio · 2025Article
- Deciphering cartilage neuro-immune interactions and innervation profile through 3D engineered osteoarthritic micropathophysiological system.Materials today. Bio · 2025Article
- Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis.Advanced healthcare materials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by changes in cartilage and subchondral bone. To date, there are no available drugs that can counteract the progression of OA, partly due to the inadequacy of current models to recapitulate the relevant cellular complexity. In this study, an osteochondral microfluidic model is developed using human primary cells to mimic an OA-like microenvironment and this study validates it as a drug testing platform. In the model, the cartilage compartment is created by embedding articular chondrocytes in fibrin hydrogel while the bone compartment is obtained by embedding osteoblasts, osteoclasts, endothelial cells, and mesenchymal stem cells in a fibrin hydrogel enriched with calcium phosphate nanoparticles. After developing and characterizing the model, Interleukin-1β is applied to induce OA-like conditions. Subsequently, the model potential is evaluated as a drug testing platform by assessing the effect of two anti-inflammatory drugs (Interleukin-1 Receptor antagonist and Celecoxib) on the regulation of inflammation- and matrix degradation-related markers. The model responded to inflammation and demonstrated differences in drug efficacy. Finally, it compares the behavior of the "Cartilage" and "Cartilage+Bone" models, emphasizing the necessity of incorporating both cartilage and bone compartments to capture the complex pathophysiology of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.